SIH Partners’s Lexicon Pharmaceuticals LXRX Stock Holding History

SIH Partners’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-23,712	Closed	-$10.9K	–	253
2025 Q1	$10.9K	Buy	+23,712	New	+$15K	﹤0.01%	270

Other funds holding LXRX

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SIH Partners's LXRX Position: Q2 2025 in Review

SIH Partners sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2025, closing a stake of 23,712 shares — an estimated $10.9K sold.

SIH Partners first reported a position in LXRX in Q1 2025 and held it in 1 quarter. The position peaked at $10.9K in Q1 2025. 123 funds tracked by Wall St. Rank hold LXRX as of Q2 2025.

SIH Partners reported no remaining Lexicon Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
SIH Partners sold 23,712 Lexicon Pharmaceuticals shares in Q2 2025, an estimated $10.9K.
SIH Partners first reported a position in Lexicon Pharmaceuticals in Q1 2025 and held it in 1 quarter.
SIH Partners's Lexicon Pharmaceuticals position peaked at $10.9K in Q1 2025.
123 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2025.

Based on SIH Partners's 13F filing for Q2 2025, filed 14 Aug 2025.